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Cellular immunotherapy is a highly effective treatment
option for patients with acute myeloid leukaemia (AML)
as shown by the low relapse rate after allogeneic stem
cell transplantation. However, many patients are not
eligible for this treatment. This has lead to the develop-
ment of various immunotherapeutic approaches that
aim at inducing autologous cellular and humoral
immune responses against AML and specifically against
residual leukaemic stem cells (LSCs).
Dendritic cells (DCs) are important regulators of the
human immune response. We have developed a three-day
DC manufacturing protocol that starts with peripheral
blood monocytes, e.g. from AML patients in remission fol-
lowing intensive chemotherapy. By using a cytokine cock-
tail containing a synthetic TLR7/8 agonist, the resulting
DCs develop improved immunogenicity. For healthy
donors as well as for AML patients, we were able to show
that these DCs display a positive costimulatory profile,
secrete high levels of IL-12p70, show chemotaxis to CCR7
ligands, and activate NK cells. After loading the DCs with
mRNA, they effectively induce antigen-specific T cell
responses with a strong type-1 polarization. Due to these
properties, this DC type seems highly suitable for applica-
tion in cancer immunotherapy.
We have recently initiated a phase I/II clinical trial for the
application of these DCs in the setting of AML postremis-
sion strategy. WT1 and PRAME were chosen as leukaemia-
associated antigens due to their overexpression on leukae-
mic blasts and specifically on cells that are enriched for
LSCs. DCs transfected with mRNA encoding CMV-pp65
are included into the vaccine as an adjuvant as well as a
surrogate antigen. 20 patients with a non-favourable risk
profile or with confirmed minimal residual disease (MRD),
but who are not eligible for allogeneic stem cell transplanta-
tion, will be included. The primary objective of this study is
to evaluate feasibility and safety of this immunotherapeutic
approach. Important secondary endpoints are immune
responses to the applied antigens and MRD control. First
results of this study will be presented.
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